# Elevance Health Inc. (ELV) — Investment Thesis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Tier:** Free primer (steps 1 & 3 of 19)  
**Sibling pages:** /stocks/ELV/financials · /stocks/ELV/memo

> This page shows the free thesis context (business model + recent catalysts).
> The full investment thesis (moat analysis, DCF, scenarios, risk register) is available
> via GET /api/v1/research/ELV/memo ($2.00, Bearer token).

## Business Model

---
ticker: ELV
step: 01
generated: 2026-05-12
source: quick-research
---

### Elevance Health, Inc. (ELV) — Business Overview

#### Business Description
Elevance Health (rebranded from Anthem in 2022) is the largest **Blue Cross Blue Shield (BCBS)** licensee in the US — operating BCBS plans in 14 states + various national Medicare Advantage + Medicaid + commercial businesses. The company is the #2 US health insurer by membership (UnitedHealth #1) and has been pivoting toward integrated healthcare services through **Carelon** (its own healthcare services brand: CarelonRx PBM + Carelon Services + Carelon Behavioral Health). FY25 revenue $167.1B (+11%). The defining 2026 narrative: like UnitedHealth + CVS-Aetna, Elevance is navigating Medicare Advantage rate-cycle pressure + Medicaid acuity trend deterioration. Q1 2026 results showed early stabilization with raised 2026 guidance.

#### Revenue Model
Four reportable segments:
- **Health Benefits** (~85% of revenue, $150B+ in FY24) — Anthem-branded BCBS commercial + individual; Medicare Advantage; Medicare Supplement; Medicaid managed care; Federal Employee Program (FEP); BlueCard.
- **CarelonRx** (~10%) — Pharmacy benefit manager; specialty pharmacy; infusion services. Replacing IngenioRx (in-house PBM).
- **Carelon Services** (~4%) — Carelon Behavioral Health, Carelon Insights (data/analytics), Carelon Post Acute Solutions.
- **Carelon Other / Corporate** (~1%) — Various smaller services.

Revenue components: ~70-75% premiums (health plans), ~20% pharmacy/services, ~5% interest income.

#### Products & Services
- **Anthem Blue Cross Blue Shield**: Commercial group + individual + Medicare + Medicaid in 14 states (California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, Wisconsin).
- **Empire BCBS, Anthem BC**: Various BCBS plans.
- **Medicare Advantage**: Anthem-branded; selectively retracting from underperforming plans in 2026.
- **Medicaid Managed Care**: 7M+ Medicaid members across ~25+ states.
- **Federal Employee Program (FEP)**: Federal government employee health plans.
- **CarelonRx PBM**: Drug benefit management for Anthem members + 3rd-party plans.
- **Carelon Behavioral Health**: Mental health / substance use; one of largest US behavioral health companies.
- **Carelon Specialty Pharmacy + Infusion**: Specialty drug fulfillment + home/center infusion services.
- **CarelonInsights**: Data analytics + decision-support tools.

#### Customer Base & Go-to-Market
- **Members**: 46M+ medical members; 7M+ Medicaid; ~9M+ Medicare-related (MA + supplement + Part D).
- **Employer Customers**: Most Fortune 500 + multi-state employers; ASO + risk-based.
- **Government**: 32% of consolidated revenue from US government agencies (Medicare + Medicaid + Federal Employee Program).
- **BCBS Geographic Footprint**: 14 BCBS states.

Distribution: Direct enterprise sales (large employers); broker/consultant channels (SMB); Medicare broker channels; Medicaid contract bidding with states.

#### Competitive Position
Elevance competes in three overlapping markets:

**Health Insurance:**
- UnitedHealth Group (UNH) — Larger; better Medicare Advantage positioning.
- CVS Health (Aetna) — Similar vertical integration with CarelonRx + Carelon Services.
- Humana — Pure-play Medicare Advantage leader.
- Cigna — Smaller; PBM via Express Scripts.

**PBM (CarelonRx):**
- Express Scripts (Cigna) — Larger PBM competitor.
- OptumRx (UnitedHealth) — Direct competitor.
- CVS Caremark — Direct competitor; together Big 3 PBMs cover ~80% of US scripts.

**Behavioral Health (Carelon):**
- Magellan Health (Centene) — Direct competitor.
- Acadia Healthcare — Smaller behavioral.

Structural advantages:
1. **BCBS scale + brand recognition** — Anthem-branded BCBS plans in 14 states; multi-decade member relationships.
2. **Vertical integration via Carelon** — Internal PBM + behavioral + services = similar moat to UNH/Optum + CVS/Aetna.
3. **National scale + state-specific BCBS franchise** — Provides both national + local market presence.
4. **32% government revenue** — Provides counter-cyclical buffer to commercial cycle.

**Active risks:**
- **Medicare Advantage rate-cycle pressure** — CMS proposed flat 2027 MA payment increases; ELV deliberately shedding MA membership in 2026 (high-teens % decline) to focus on profitable HMO + DSNP.
- **Medicaid margins underwater** — FY26 guide projects ~-1.75% operating margin; acuity trend deterioration + state rate lag.
- **MLR elevated at 90.2%** — Higher medical-cost trend than historical norms.
- **Revenue declining in 2026** — Low single-digit % decline guided as ELV de-emphasizes underperforming risk-based businesses.

#### Key Facts
- Founded: 1944 (Anthem Insurance Companies); 2004 BCBS aggregation; rebranded Elevance 2022
- Headquarters: Indianapolis, Indiana
- Employees: ~104,000+
- Exchange: NYSE
- Sector / Industry: Health Care / Health Care Plans
- Market Cap: ~$95B
- FY2024 Revenue: $175.2B
- FY2025 Revenue: $167.1B (Health Benefits decline; Medicare Advantage attrition)
- Medical Members: ~46M+
- Medicaid Members: ~7M+
- Medicare Advantage Members: Declining ~17% in 2026 to focus on profitable mix
- BCBS States: 14
- FY2026 Operating Revenue Guide: Low single-digit % decline
- FY2026 Medical Loss Ratio: 90.2% ± 50 bps
- Dividend Yield: ~1.7%
- CEO: Gail Boudreaux

## Recent Catalysts

---
ticker: ELV
step: 12
generated: 2026-05-12
source: quick-research
---

### Elevance Health, Inc. (ELV) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Q1 2026 results raised guidance** — Early operational stabilization; $1.8B Q1 profit; FY26 EPS guide raised.
2. **Deliberate Medicare Advantage de-risking (-17% membership)** — ELV proactively exiting underperforming MA plans + IRA-impacted Part D plans; concentrating on profitable HMO + DSNP. Margin recovery expected through 2026-27.
3. **BCBS scale + brand moat** — 14 BCBS states + Anthem brand + 46M+ members = irreplaceable competitive position.
4. **Carelon services growing** — Internal PBM + Behavioral Health + Insights = same vertical integration strategy as UnitedHealth Optum + CVS Caremark.
5. **Cheap valuation (~11x FY26 P/E)** — Discount to UNH (~17x) + CVS (~10x); reflects Medicare Advantage cycle pressure already priced in.
6. **4.5%+ combined capital return yield** — Dividend (~1.7%) + buybacks (~3%+); sustainable through cycle.
7. **32% revenue from government** — Counter-cyclical buffer to commercial economic cycles.
8. **Q4 2025 Health Benefits +11% YoY** — Sequential momentum suggests cycle bottoming.

#### Bear Case Risks

1. **Medicare Advantage rate cycle uncertainty** — CMS proposed essentially flat 2027 MA payments + IRA effects; ELV's MA business hit hardest in industry (deliberately exited).
2. **Medicaid margins at -1.75%** — Acuity trend deterioration + state rate lag; could continue through 2026.
3. **MLR elevated at 90.2%** — Multi-year medical cost trend remains above historical norms.
4. **PBM regulation tail risk** — Bipartisan congressional pressure on PBM rebate retention; could impact CarelonRx materially.
5. **2026 revenue declining low single-digit %** — Operating revenue contraction creates negative narrative even though deliberate.
6. **Operating cash flow vs. peer comparison** — ELV cash conversion is below UNH peer; suggests less operating leverage from scale.
7. **CEO succession risk** — Gail Boudreaux has been CEO since 2018; eventual succession transition.
8. **State Medicaid rate negotiations** — Long lag between acuity trend + rate increases; multi-quarter margin pressure.

#### Upcoming Events
- **Q2 2026 earnings (mid-July 2026)**: Mid-year guide check + MA membership trajectory.
- **Q3 2026 earnings (mid-October 2026)**: Open enrollment results.
- **CMS 2027 MA rate finalization (April 2027)**: Multi-year impact on Anthem MA profitability.
- **Medicare Advantage open enrollment (Oct-Dec 2026)**: 2027 plan year member additions.
- **PBM regulation Senate/House votes**: Ongoing through 2026-27 Congress.
- **State Medicaid rate negotiations**: Quarterly updates by state.
- **Annual dividend hike**: Typical Q1 cadence.

#### Analyst Sentiment
Consensus rating is **Hold / Buy** (~55% Buy, 40% Hold, 5% Sell). Price targets cluster $450–520 vs. trading ~$405–435 (~10–25% implied upside). Bull case targets ~$580 on Medicare Advantage rate cycle improvement + Carelon scaling; bear case ~$320 on continued cycle deterioration + PBM regulation. Morgan Stanley, BofA, Wells Fargo maintain Buy/Overweight; UBS at Neutral; Goldman at Buy; Citi at Buy.

#### Research Date
Generated: 2026-05-12

## Full Investment Thesis (Premium)

The full research tier adds these thesis-critical dimensions:

- Moat Analysis — durable competitive advantages, switching costs, network effects
- Investment Thesis — variant perception, what has to be true, why market may be wrong
- Bull / Base / Bear Scenarios — probability weights, catalysts, price targets
- Risk Register — macro, competitive, execution, regulatory risks with materiality ratings
- Management Quality — capital allocation track record, incentive alignment
- DCF Valuation — 10-year model with sensitivity matrix

**API endpoint:** GET /api/v1/research/ELV/memo

## Navigation

- Overview: /stocks/ELV
- Financials: /stocks/ELV/financials
- Thesis (this page): /stocks/ELV/thesis
- Investment Memo: /stocks/ELV/memo
- Coverage universe: /stocks